NK Cell Therapy Pipeline Assessment | Insights Into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, Key Companies

Delveinsight Business Research LLP
As per DelveInsight’s assessment, there are approx. 100+ key companies which are developing Natural Killer (NK) cell therapy. Among several key companies active in the domain, currently, Nektar therapeutics have its Natural Killer (NK) cell therapy drug candidates in the most advanced phase, i.e. Phase III stage of clinical development.

“NK Cell Therapy Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the NK Cell Therapy Market

The NK Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

NK Cell Therapy Pipeline Analysis

The report provides insights into: 

The report provides detailed insights about companies that are developing therapies in the NK Cell therapeutics domain with aggregate therapies developed by each company for the same.

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

Key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

NK Cell Therapies under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NK Cell Therapy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

NK Cell Therapy Therapeutics Landscape

Several major pharma and biotech giants are actively working in the NK Cell Therapy Therapeutics Market. Some of the key companies in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), among others.

Some of the key NK Cell Therapies covered in the report include:

NKTR-214 (Nektar Therapeutics)

Monalizumab (Innate Pharma)

Bemarituzumab (Five Prime Therapeutics)

ALT 803 (ImmunityBio) 

CellProtect (XNK Therapeutics)

K-NK002 (Kiadis Pharma)

NK-92 (ImmunityBio)

WU-NK-101 (Wugen)

Anti-CD33 CAR-NK cells (PersonGen BioTherapeutics)

ALECSAT (CytoVac)

And many more

Get More Detailed Insights Into the Emerging Therapies & Key Companies –    https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. NK Cell Therapy Current Treatment Patterns

4. NK Cell Therapy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. NK Cell Therapy Late Stage Products (Phase-III)

7. NK Cell Therapy Mid-Stage Products (Phase-II)

8. NK Cell Therapy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. NK Cell Therapy Discontinued Products

13. NK Cell Therapy Product Profiles

14. Key Companies in the NK Cell Therapy Market

15. Key Products in the NK Cell Therapy Therapeutics Segment

16. Dormant and Discontinued Products

17. NK Cell Therapy Unmet Needs

18. NK Cell Therapy Future Perspectives

19. NK Cell Therapy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Latest Healthcare Reports by DelveInsight

Orthobiologics Market

Orthobiologics Market” research report delivers an in-depth understanding of the Orthobiologics market size, share, trends, growth analysis, and forecast in the 7MM as well as the key companies and emerging therapies in the therapeutics domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Generated by Feedzy
%d bloggers like this: